To include your compound in the COVID-19 Resource Center, submit it here.

RB1 alterations predict survival in mCRPC patients treated with Zytiga or Xtandi

TECHNIQUES CATEGORY: Biomarkers

TECHNOLOGY: Gene profiling

Alterations in RB1 could help predict survival in mCRPC patients treated with Zytiga or Xtandi.

Read the full 194 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE